These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11446652)

  • 21. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.
    Dragon-Durey MA; Frémeaux-Bacchi V; Loirat C; Blouin J; Niaudet P; Deschenes G; Coppo P; Herman Fridman W; Weiss L
    J Am Soc Nephrol; 2004 Mar; 15(3):787-95. PubMed ID: 14978182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement factor H related proteins in immune diseases.
    Skerka C; Zipfel PF
    Vaccine; 2008 Dec; 26 Suppl 8():I9-14. PubMed ID: 19388158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation.
    Jha V; Murthy MS; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
    Ren Fail; 1998 Nov; 20(6):845-50. PubMed ID: 9834983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
    Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
    Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.
    Høgåsen K; Jansen JH; Mollnes TE; Hovdenes J; Harboe M
    J Clin Invest; 1995 Mar; 95(3):1054-61. PubMed ID: 7883953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement factor H and the hemolytic uremic syndrome.
    Atkinson JP; Goodship TH
    J Exp Med; 2007 Jun; 204(6):1245-8. PubMed ID: 17548524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
    Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
    Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement factor H: using atomic resolution structure to illuminate disease mechanisms.
    Barlow PN; Hageman GS; Lea SM
    Adv Exp Med Biol; 2008; 632():117-42. PubMed ID: 19025119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
    Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
    Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
    Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
    J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The factor H protein family.
    Zipfel PF; Jokiranta TS; Hellwage J; Koistinen V; Meri S
    Immunopharmacology; 1999 May; 42(1-3):53-60. PubMed ID: 10408366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical hemolytic uremic syndrome due to factor H autoantibody.
    Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
    Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor H--US?
    Warwicker P; Goodship JA; Goodship TH
    Nephrol Dial Transplant; 1998 Aug; 13(8):1921-3. PubMed ID: 9719138
    [No Abstract]   [Full Text] [Related]  

  • 35. Complement factor H and the haemolytic uraemic syndrome.
    Taylor CM
    Lancet; 2001 Oct; 358(9289):1200-2. PubMed ID: 11675053
    [No Abstract]   [Full Text] [Related]  

  • 36. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
    Manuelian T; Hellwage J; Meri S; Caprioli J; Noris M; Heinen S; Jozsi M; Neumann HP; Remuzzi G; Zipfel PF
    J Clin Invest; 2003 Apr; 111(8):1181-90. PubMed ID: 12697737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Properdin, factor H, factor I].
    Ohsawa I; Tomino Y
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():77-81. PubMed ID: 20942006
    [No Abstract]   [Full Text] [Related]  

  • 38. Complement dysregulation in glomerulonephritis.
    Kaartinen K; Safa A; Kotha S; Ratti G; Meri S
    Semin Immunol; 2019 Oct; 45():101331. PubMed ID: 31711769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor H family proteins: on complement, microbes and human diseases.
    Zipfel PF; Skerka C; Hellwage J; Jokiranta ST; Meri S; Brade V; Kraiczy P; Noris M; Remuzzi G
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):971-8. PubMed ID: 12440956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.